Price T Rowe Associates Inc Precigen, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Precigen, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 165,152 shares of PGEN stock, worth $234,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165,152
Previous 159,848
3.32%
Holding current value
$234,515
Previous $215,000
11.63%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PGEN
# of Institutions
142Shares Held
145MCall Options Held
208KPut Options Held
43.7K-
Third Security, LLC83.5MShares$119 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD17.5MShares$24.8 Million1.27% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$14.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.77MShares$9.61 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.03MShares$4.3 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $296M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...